Categories Earnings, Health Care

Catabasis Pharmaceuticals (NASDAQ: CATB): Q4 2019 Earnings Snapshot

— Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) reported a net loss of $6.6 million or $0.55 per share for the fourth quarter of 2019, compared to a loss of $6.1 million or $0.85 per share last year. Analysts had forecast a loss of $0.61 per share.

— Being a development-stage biopharmaceutical company, Catabasis did nor record revenues in the December-quarter

— Research & Development expenses increased 16% year-over-year to $4.3 million during the three-month period

— At $2.5 million, selling, general and administrative expenses were up 4% from the year-ago period

— As of December 2019, cash, cash equivalents and short-term investments were $36.2 million, compared to $40.6 million as of September 2019

— Expects to fund operations through a potential NDA filing and into the third quarter of 2021, using available cash

— Expects to publish top results from the phase-3 PolarisDMD trial of edasalonexent, in Duchenne muscular dystrophy, in the fourth quarter of 2020

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Most Popular

Target Corp posts strong results in Q4: Infographic

Target Corporation (NYSE: TGT) reported fourth-quarter 2020 financial results before the opening bell today. The department store chain reported Q4 revenue of $28.3 billion, up 21% year-over-year and higher than

Key highlights from Autodesk (ADSK) Q4 2021 earnings results

Autodesk, Inc. (NASDAQ: ADSK) today reported its fourth quarter financial results for the period ended January 31, 2021. Net income for the fourth quarter was $911.3 million, or $4.10 per

Infographic: Beyond Meat (BYND) reports wider Q4 loss; Revenue up 4%

Beyond Meat (NASDAQ: BYND), a specialist in plant-based meat substitutes, Thursday reported a wider loss for the fourth quarter, despite an increase in revenues. The numbers also missed the consensus

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top